Tempus AI TEM stock saw a positive improvement to its Relative Strength (RS) Rating on Thursday, rising from 66 to 78. Please ...

Tempus AI’s TEM stock has surged nearly 13% since its second-quarter 2025 earnings release. The quarter saw strong top-line ...

Bioventus Inc. (NASDAQ:BVS) is one of the best medical device stocks to buy according to analysts. On August 7, Craig-Hallum ...

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting ...

In addition to Stifel Nicolaus, Tempus AI, Inc. Class A also received a Hold from Piper Sandler’s David Westenberg in a report issued today. However, on August 8, Needham reiterated a Buy rating on ...

Tempus AI achieves strong revenue growth and beats expectations, but ongoing losses and execution risks temper enthusiasm.

In a report released today, Rachel Vatnsdal from J.P. Morgan maintained a Hold rating on Tempus AI, Inc. Class A, with a price target of $60.00. The company’s shares closed last Friday at $60.87. Take ...

Alphabet, UnitedHealth Group, Salesforce, Oracle, ServiceNow, Palo Alto Networks, and Tempus AI are the seven Healthcare ...

U.S. President Donald Trump launched a scathing attack on former House speaker Nancy Pelosi and her husband Paul Pelosi, on ...

The stock of Tempus AI (NASDAQ: TEM) gave back some of its gains after surging early in Friday's trading, but it still ended ...

In trading on the Nasdaq as of 1:17 p.m. Central, Tempus' stock price was $60.65, up 3.2% from the previous day's close.